22 January 2026
Scancell Holdings plc
("Scancell" or the "Company")
Notice of Interim Results and Investor Presentation
Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, will announce its interim financial results for the six months ended 31 October 2025 and provide a business update on progress achieved post-period, on Thursday 29 January 2026.
Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast for analysts and investors on the day of the results at 14:00 GMT.
If you would like to join the webcast, please follow this link:
Interim Financial Results for the six months ending 31 October 2025 | SparkLive | LSEG
|
For further information, please contact: |
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Phillip L'Huillier, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl/ Will Goode, Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking)
|
|
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson, Claes Spang
|
|
|
Investor and media relations |
|
|
Mary-Ann Chang |
+44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk
|
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified - enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
